Skip to main content
. 2019 Jan 30;111(9):961–969. doi: 10.1093/jnci/djy227

Table 3.

SMR and AER for selected cancers by years since treatment for hereditary retinoblastoma

Cancer type Age, y
<15 15–29 30–44 45–59 ≥60
All subsequent cancers
 O 55 69 74 55 14
 SMR* (95% CI) 71.1 (53.5 to 92.5) 89.9 (70.0 to 113.8) 33.6 (26.4 to 42.2) 14.1 (10.7 to 18.4) 6.7 (3.6 to 11.2)
 AER 38.0 62.1 97.6 196.4 327.5
Bone
 O 31 33 9 5 1
 SMR* (95% CI) 886.5 (602.2 to >1000) 695.9 (479.0 to 977.4) 591.4 (269.9 to >1000) 539.3 (173.8 to >1000)
 AER 21.7 30.0 12.2 19.2
Soft tissue sarcoma and connective tissue
 O 4 12 18 14 4
 SMR* (95% CI) 166.1 (44.7 to 425.2) 316.4 (163.3 to 552.8) 410.1 (242.9 to 648.1) 380.5 (207.8 to 638.5) 318.6 (85.7 to 815.6)
 AER 2.8 10.9 24.4 53.6 109.8
Nasal cavities, middle ear and sinus
 O 4 5 2 4 0
 SMR* (95% CI) >1000 (>1000 to >1000) >1000 (969.8 to >1000) 521.6 (58.6 to >1000) 916.6 (246.6 to >1000)
 AER 2.8 4.5 2.7 15.4
Melanoma
 O 1 8 4 2 0
 SMR* (95% CI) 210.4 (90.6 to 414.5) 37.9 (10.2 to 97.1) 21.3 (2.4 to 77.0)
 AER 7.2 5.3 7.3
Brain, and other parts of the nervous system
 O 8 0 7 2 0
 SMR* (95% CI) 44.6 (19.2 to 87.9) 42.9 (17.2 to 88.4) 12.6 (1.4 to 45.4)
 AER 5.5 9.3 7.1
Lung and trachea
 O 1 1 5 5 0
 SMR* (95% CI) 15.5 (5.0 to 36.1) 4.8 (1.5 to 11.2)
 AER 6.4 15.2
Corpus uteri
 O 0 0 4 4 1
 SMR* (95% CI) 202.5 (54.5 to 518.4) 81.2 (21.8 to 207.9)
 AER 11.7 31.1
Bladder
 O 0 0 2 4 1
 SMR* (95% CI) 130.0 (14.6 to 469.4) 79.0 (21.3 to 202.3)
 AER 2.7 15.2
*

SMRs, CIs, and AERs not presented for deaths <2. AER = absolute excess risk per 10 000 person-years; CI = confidence interval; O = observed number of cancer deaths; SMR = standardized mortality ratio.